Newswise — At the 7th Human Amyloid Imaging conference held last month in Miami, Florida, 250 experts discussed the hottest topics in Alzheimer’s disease brain imaging. What’s in store for 2013? Compounds that image tau—one of the disease’s toxic brain proteins—sat front and center. These tracers may soon allow scientists to scan a person’s brain for tangles, the partners in crime with amyloid plaques. Scientists can already see plaques in the brain using amyloid imaging compounds. The FDA approved one of those amyloid tracers for clinical use last year, and in Miami an expert panel proposed guidelines for their use. With these ground rules, the panel hope to ensure responsible use of these scans, which are not, as some might mistakenly believe, a clear-cut “Alzheimer’s test.”

Though the FDA has accepted only one amyloid imaging ligand for clinical use so far, several more are being used in research studies. These agents light up scans at different intensities, making direct comparison impossible. At the meeting, an inventor of this technology proposed a way to merge the values into one standard unit. This “centiloid” scale could give experts a common language to use across labs and between studies.

A five-part series by Alzforum covers these points and more.

About Alzforum: The Alzheimer Research Forum (www.alzforum.org), founded in 1996, is the web's most dynamic scientific community dedicated to understanding Alzheimer disease and related disorders. Access to the web site is free to all. The Forum’s editorial priorities are as diverse as the needs of the research community. The web site reports on the latest scientific findings, from basic research to clinical trials; creates and maintains public databases of essential research data and reagents; and produces discussion forums to promote debate, speed the dissemination of new ideas, and break down barriers across the numerous disciplines that can contribute to the global effort to cure Alzheimer's disease.

The ARF team of professional science writers and editors, information technology experts, web developers and producers all work closely with its distinguished and diverse Advisory Board to ensure a high quality of information and services. The Alzheimer Research Forum is an independent nonprofit organization supported by grants and individual donations. The web site does not endorse any specific product or scientific approach.